Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity

Haijun Tang1,2, Long Gao1,2, Zhao Wu1,2, Fang Meng1,2, Xin Zhao1,2, Yun Shao1,2, Xiaohua Shi3, Shigang Qiao4, Jianzhong An4, Xiaohong Du4* and F. Xiao-Feng Qin1,2*

1 Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 2 Suzhou Institute of Systems Medicine, Suzhou, China, 3 Department of Gastroenterology, The Affiliated Suzhou Science and Technology Town Hospital of Nanjing Medical University, Suzhou, China, 4 Institute of Clinical Medicine Research, Suzhou Science and Technology Town Hospital, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China

SARS-coronavirus 2 (SARS-CoV-2), pathogen of coronavirus disease 2019 (COVID-19), is constantly evolving to adapt to the host and evade antiviral immunity. The newly emerging variants N501Y.V1 (B.1.1.7) and N501Y.V2 (B.1.351), first reported in the United Kingdom and South Africa respectively, raised concerns due to the unusually rapid global spread. The mutations in spike (S) protein may contribute to the rapid spread of these variants. Here, with a vesicular stomatitis virus (VSV)-based pseudotype system, we demonstrated that the pseudovirus bearing N501Y.V2 S protein has higher infection efficiency than pseudovirus with wildtype (WT) and D614G S protein. Moreover, pseudovirus with N501Y.V1 or N501Y.V2 S protein has better thermal stability than WT and D614G, suggesting these mutations of variants may increase the stability of SARS-CoV-2 S protein and virion. However, the pseudovirus bearing N501Y.V1 or N501Y.V2 S protein has similar sensitivity to inhibitors of protease and endocytosis with WT and D614G. These findings could be of value in preventing the spread of virus and developing drugs for emerging SARS-CoV-2 variants.

Keywords: SARS-CoV-2, N501Y.V1, N501Y.V2, infectivity, thermal stability

INTRODUCTION

The coronavirus disease 2019 (COVID-19) pandemic has become a great threat to the health of human beings. As of May 23, 2021, more than 160 million confirmed cases and approximately 3.4 million deaths have been reported worldwide (https://covid19.who.int). SARS-coronavirus 2 (SARS-CoV-2), pathogen of COVID-19, can cause infection of multiple organs throughout the body, mainly respiratory, digestive, circulatory, genitourinary and nervous systems. Although most symptoms of COVID-19 patients are mild, some may have severe pneumonia, even multiple organs failure, particularly in older people and those pre-existing chronic diseases (Lv et al., 2020).

SARS-CoV-2 uses spike (S) protein to bind host receptor angiotensin-converting enzyme 2 (ACE2), followed by membrane fusion and the release of viral RNA genome into the cytoplasm (Li et al., 2003; Benton et al., 2020; Shang et al., 2020; Wan et al., 2020; Zhou et al., 2020). As a type I membrane fusion protein, SARS-CoV-2 S protein composed of S1 and S2 subunits. S1 subunit
mediates the attachment of virion to host cell, while S2 subunit mediates the fusion between viral and cellular membrane (Belouzard et al., 2009; Walls et al., 2020; Watanabe et al., 2020). Therefore, the S protein is essential to viral infectivity and transmissibility in the host (Hulswit et al., 2016). Before the membrane fusion, SARS-CoV-2 S protein needs to be cleaved by proteases, such as furin, cathepsins, trypsin, or transmembrane protease serine 2 (TMPRSS2). The cleavage of S protein by these proteases greatly affects the efficiency of virus infection on host cells (Palacios et al., 2020).

RNA viruses have a high mutation rate in the process of host transmission. Some mutations may alter viral pathogenicity, virulence, and/or transmissibility (Duffy, 2018). The mutations of SARS-CoV-2 S protein probably alter virus infectivity. In particular, D614G mutation was first identified in Europe, then replaced previously circulating lineages and led to a global pandemic (Korber et al., 2020). Studies show that the D614G substitution leads to the enhancement of viral replication and infectivity in human lung epithelial cells (Hou et al., 2020; Korber et al., 2020). Since December 2020, emergence of new SARS-CoV-2 variants N501Y.V1 (also known as B.1.1.7) in the United Kingdom and N501Y.V2 (also known as B.1.351) in South Africa (James et al., 2020; Kirby, 2021; Makoni, 2021; Rubin et al., 2021; Tegally et al., 2021) aroused widespread concern because of their extensive mutations and enhanced transmissibility.

The SARS-CoV-2 N501Y.V1 lineage has 17 non-synonymous mutations and deletions, and many of them locate in the S protein. N501Y.V2 lineage includes ten mutations in the S protein, and three of them are located in the receptor binding domain (RBD) (K417N, E484K, and N501Y). As a common mutation of N501Y.V1 and N501Y.V2, N501Y mutation was first reported in a mouse model and hereafter identified in populations of many countries and regions (Gu et al., 2020; James et al., 2020; Kirby, 2021). In the mouse model, N501Y mutation enhances the binding affinity of SARS-CoV-2 S protein with mouse ACE2, and increase infectivity in mouse lung tissue (Gu et al., 2020). E484K mutation was first identified in N501Y.V2, and was reported to be associated with escaping from neutralizing antibodies (Baum et al., 2020; Weisblum et al., 2020). Interestingly, N501Y.V3 (also known as P.1) lineage in Brazil almost has the same three RBD mutations as N501Y.V2, and was reported to be associated with escaping from neutralizing antibodies (Baum et al., 2020; Weisblum et al., 2020). The S genes with single-site mutation were obtained from Sanger’s DNA sequencing at Genewiz Biotechnology Co., Ltd. The sequencing results of SARS-CoV-2 S mutants are presented in Supplementary Figures S1A–D. The primers used for mutagenesis are listed in Supplementary Tables S1, S2.

**Cell Lines**

Human cell lines (293T, Calu-3, Calu-3, Huh7, H460, A549, NCI-H1299), African monkey kidney Vero cell, and mouse cell lines (MC38 and LLC-JSP) were obtained from American Type Culture Collection. Cell stably expressing human ACE2 and/or TMPRSS2 (293T-hACE2/293T-hACE2-TMPRSS2, Caco2-hACE2, A549-hACE2) were constructed with lentiviral mediated gene transduction. H460 cell line was cultured in RPMI (HyClone), and the others were cultured in DMEM (HyClone). All above cells were maintained in the medium containing 10% fetal bovine serum (FBS, Gibco) and 100 U/mL of Penicillin-Streptomycin solution (Gibco). The cells were cultured in an incubator with atmosphere of 5% CO₂ at 37°C.

**Production and Quantification of SARS-CoV-2 Pseudovirions**

Pseudovirions bearing SARS-CoV-2 S protein were generated according to published protocols (Nie et al., 2020). Briefly, on the day before transfection, 5x10⁶ 293T cells were seeded into 10 cm cell culture dish. The next day, when the cells reached 70–90% confluent, 293T cells were transfected to express the S gene properties and biological characteristics of these variants remain elusive. In this study, we constructed pseudoviruses bearing SARS-CoV-2 S protein with mutations of N501Y.V1 and N501Y.V2 variants. We investigated the infectivity, S protein cleavage, thermal stability and drug inhibition properties of N501Y.V1 and N501Y.V2 pseudoviruses. This research promotes our understanding to the evolution of SARS-CoV-2 variants as well as the development of COVID-19 therapeutic drugs.

**MATERIALS AND METHODS**

**Construction of Expression Plasmids**

Expression vector pcDNA3.1-2S (GenBank: MT_613044) with codon-optimized S gene of SARS-CoV-2 was obtained from Genscript Biotechnology Company. In order to effectively integrate S protein into pseudovirion, the last 19 amino acids of S protein were replaced with HA tag according to previously reported with modifications (Whitt, 2010; Zettl et al., 2020). The S genes with single-site mutation were obtained with the site-directed mutagenesis kit (KOD). To construct variants with multiple mutations, the plasmids were synthesized with ClonExpress Ultra One Step Cloning Kit (Vazyme). Briefly, primers containing site-directed mutation and homologous sequences were designed for PCR amplification to generate several fragments carrying different mutations, then these overlapping fragments were ligated together using homologous recombination to re-assemble the expression vector with complete S gene coding sequence. All the resulting S protein expression vectors were verified by Sanger’s DNA sequencing at Genewiz Biotechnology Co., Ltd. The sequencing results of SARS-CoV-2 S mutants are presented in Supplementary Figures S1A–D. The primers used for mutagenesis are listed in Supplementary Tables S1, S2.
with lipofectamine 3000 (Invitrogen). 12 h post transfection, the cells were infected with G*ΔG-VSV dual reporter virus, a GP-deleted replication defective recombinant VSV virus containing firefly luciferase and eGFP reporter genes (kindly provided by UltraImmune Inc., Patent pending CN112760297A). 6 h post infection, the cell supernatant was discarded, and the cells were gently washed twice with PBS. Next, 10 mL fresh DMEM medium was added into the cell culture dish. 24 h post infection, the supernatant containing pseudovirions was harvested, then centrifuged at 3500 g for 5 min to remove the cell debris, and stored at -80°C in 1.5 mL aliquots until use.

Pseudovirions were quantified by RT-qPCR. Virus RNA was extracted from 200 µL of supernatant containing pseudovirions with Viral RNA/DNA Mini kit, and reversed to cDNA by PrimeScript™ RT reagent Kit (Takara). Pseudovirions quantification was performed using FastStart Essential DNA Green Master (Roche) following the manufacturer’s protocols. The copy numbers of pseudovirions were calculated by the VSV-P protein gene. Primers are listed in Supplementary Table S3.

Infection Assay
Before the infection assay, the pseudovirions were normalized to the same amount by quantitative RT-qPCR. The day before virus infection, 2x10⁷/100 µL cells were seeded into 96-well plates. The next day, cells were infected with 100 µL of media containing pseudovirions. 16 or 24 h post infection, cells were lysed with 60 µL diluted passive lysis buffer (Promega) at room temperature for 10 min. The infection efficiency of the pseudovirus was detected by measuring the activity of luciferase using Luciferase Assay System (Promega). For analysis of pseudovirus entry into 293T-hACE2 cells at indicated time points, images were captured in each well with a Nikon inverted microscope ECLIPSE Ts2 epifluorescence microscope. Each group contained 4 replicates, and each experiment was repeated at least two times.

Thermal Stability Assay of SARS-CoV-2 Pseudovirions
Pseudovirions incorporated with S protein of SARS, SARS-CoV-2 WT, D614G, N501Y.V1 and N501Y.V2 lineages were diluted with DMEM and incubated in a 37°C or 42°C water bath. At indicated time points, 100 µL DMEM containing the pseudovirions was taken out and added into the wells with 293T-hACE2. 24 h post infection, the infection efficiency of pseudovirus was detected by measuring the activity of luciferase. The relative infection efficiency of pseudovirus was calculated by dividing the relative luminescence unit (RLU) values at each time point by the mean viral RLU at 0 h.

SARS-CoV-2 S Expression and Incorporation Assay
In order to verify the expression of S protein in cells, the SARS-CoV-2 S expression vectors were transfected into 293T cells with lipofectamine 3000 (Invitrogen). 40 h post transfection, cells were lysed by RIPA Lysis Buffer (Beyotime) for 30 min on ice. In order to analyze incorporation of S protein into pseudotyped particles, VSV pseudovirions were concentrated with PEG8000. Briefly, medium containing pseudovirions was loaded by 6% PEG8000 and 0.1M NaCl, and shaken on the ice overnight. Next, the mixture was centrifugated (10,000 g) for 120 min at 4°C. After that, the supernatant was discarded, and the residual volume was mixed with 50 uL RIPA.

All the samples were heated at 96°C for 10 minutes, and then the expression of S protein was detected by SDS-PAGE. After protein transfer, the nitrocellulose membrane was blocked by 5% milk for 1 h. Then the membranes were blotted with primary antibodies, followed by incubation with a secondary antibody and visualized by Bio-Rad ClhmiDoc MP Bio-Rad Laboratorigs. The primary antibodies used for western blot analysis were as follows: mouse anti-SARS-CoV/SARS-CoV-2 (COVID-19) spike [1A9] (Genetex, 1:2000), mouse anti-β-actin monoclonal antibody (TransGen Biotech, 1:2000), mouse anti-VSV matrix protein (Kerafast, 1:2500). We used a horseradish peroxidase-linked anti-mouse IgG antibody (Cell Signaling Technology, 1:5000) as secondary antibody.

Effects of Endocytosis and Protease Inhibitors on Pseudovirion Entry
For experiments involving endocytosis and protease inhibitors, 293T-hACE2 or 293T-hACE2-TMPRSS2 cells were pretreated with either endocytosis inhibitors (Chloroquine, MedChemExpress, 0-10 µM; Tetradrine, Sigma-Aldrich, 0-2 µM and Apilimod, MedChemExpress, 0-100 nM) or protease inhibitors (E64d, MedChemExpress, 0-5 µM; Camostat, MedChemExpress, 0-100 µM) for 2 h. Then the pseudovirions was added into the corresponding wells of plates. 24 h post infection, cells were lysed, and the infection efficiency of viruses was detected by measuring the luciferase activity using Luciferase Assay System.

Statistical Analysis
The GraphPad Prism 7 software package was used for all statistical analyses. The unpaired two-tails Student’s t-test was used to determine the statistical significance. The values were presented as mean ± SEM and p < 0.05 was defined as statistically significant [ns represents no significant difference, p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), p < 0.0001 (****)].

RESULTS
The Expression and Pseudovirion Incorporation of SARS-CoV-2 S Protein
The purpose of this study was to gain insights into the differences of N501Y.V1 and N501Y.V2 lineages with previous WT and D614G. For this, we first constructed S genes expression vectors of N501Y.V1 variant (with all nine mutations) and N501Y.V2 RBD mutations (K417N, E484K, N501Y and D614G) (Figure 1A). Then, the S protein expression in 293T cells was detected by western blot. There were two major bands, 180 kDa band (full-length S protein) and 90 kDa band (cleaved S protein, S2 subunit). The full-length S protein was observed in cells, but cleaved S protein was not obvious (Figure 1B). We also detected
the S protein expression of single-site mutation in N501Y.V1 and N501Y.V2 RBD. The differences in cleavage of S protein with point mutations were also not observed (Figure 1C).

The efficiency of S protein incorporation into pseudovirions was analysed by western blot using antibody against SARS-CoV-2 spike and VSV-M. The results indicated that all four S proteins successfully incorporate into pseudovirions, and the cleaved S protein (S2 subunit) is at the similar level, except for a slightly weakened band in N501Y.V1 (Figure 1B).

**Infectivity of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Lineages**

Replication-defective VSV pseudovirus incorporated with S protein from coronavirus faithfully reflect the key aspects of virus entry into host cells, and have been applied in neutralizing antibody quantification and entry mechanism study of SARS-CoV-2 (Kleine-Weber et al., 2019; Condor Capcha et al., 2020; Nie et al., 2020a; Nie et al., 2020b). Moreover, several monoclonal antibodies targeting S protein of SARS-CoV-2 could completely inhibit the infection of VSV-based pseudovirus (data not shown). To determine the infectivity of N501Y.V1 and N501Y.V2 variants, a panel cell lines originated from human and animals were infected with VSV pseudoviruses of SARS-CoV-2 WT, D614G, N501Y.V1 and N501Y.V2 RBD (Figure 2A). All four pseudoviruses could efficiently infect certain cell lines, including 293T-hACE2-TMPRSS2, 293T-hACE2, Huh-7, Caco-2, Caco2-hACE2, Vero, Calu-3, A549-hACE2 and H460. Compared with WT, pseudovirus bearing S protein with D614G mutation (including D614G, N501Y.V1 and N501Y.V2 RBD) were significantly more infectious in
several susceptible cells. More importantly, N501Y.V2 RBD pseudovirus has higher infection efficiency than D614G in all susceptible cells, while N501Y.V1 has no obviously difference. Next, we detected the infectivity of N501Y.V2 pseudovirus to different cells (Supplementary Figures S2A–E). Compared with D614G, N501Y.V2 pseudovirus had significant difference in the infection efficiency of 293T-hACE2-TMPRSS2, Caco2 and Caco2-hACE2 cells. However, the infection efficiency of N501Y.V1, V2 RBD pseudovirus is higher than N501Y.V2 in some susceptible cells. In addition, we detected the infection efficiency of SARS-CoV-2 WT, D614G, N501Y.V1 and N501Y.V2 RBD in target cells at 10 h, 14 h, 18 h, 24 h, and 36 h. The infection rate of N501Y.V1 at different time point was also higher than that of D614G (Figures 3A–D). We also tested the infectivity of pseudoviruses with single-site S protein mutations in 293T-hACE2, Caco2-hACE2 and Vero cells (Figure 2B). Compared with WT pseudovirus, the viral infectivities of D614G and HV69-70 deletion were increased in all three cells. In contrast, T716I, A570D, D118H and A701V mutations caused a modest reduction in viral infectivity. It is worth noting that the N501Y mutation does not result in a significant change in the infectivity of the pseudovirus.

**Thermal Stability Analysis of N501Y.V1 and N501Y.V2 Pseudovirions**

In order to study the effect of S mutations of N501Y.V1 and N501Y.V2 lineages on the stability of the virus, we measured the infectivity decay of pseudoviruses incorporated S protein of SARS, SARS-CoV-2 WT, D614G N501Y.V1 and N501Y.V2 RBD over time at 37°C (normal body temperature) and 42°C (possible body temperature in fever). The infectivity of the five pseudoviruses decreased faster at 42°C than 37°C (Figures 4A, B). It is worth noting that pseudovirions bearing S protein of N501Y.V1 and N501Y.V2 RBD variants retained higher infectivity than WT and D614G at any temperature (Figures 4A, B). In addition, we detected the thermal stability of N501Y.V2 pseudovirus at 37°C and 42°C (Supplementary Figures S3A–D). Similar to N501Y.V2 RBD mutation, the stability of N501Y.V2 pseudovirus was significantly higher than that of WT and D614G.

We also examined the effect of single-site mutations of N501Y.V1 and N501Y.V2 lineages on the thermal stability of SARS-CoV-2. We measured the infectivity decay of pseudoviruses bearing single-site mutations at 37°C or 42°C (Figures 4C–F). The results indicated that pseudovirions bearing HV69-70 deletion, 144 deletion, E484K, D614G, P681H, S982A or D1118H single-site mutations were more stable than SARS-CoV-2 WT, whereas A570D and T716I mutations decrease the stability of SARS-CoV-2 pseudovirion. Our findings show that, the S protein mutations of N501Y.V1 and N501Y.V2 variants may increase the conformational stability of spike to promote the infectivity of SARS-CoV-2 virion.

**Effect of Cathepsin Inhibitors and Serine Protease Inhibitor on Virus Entry**

The endosomal cysteine proteases cathepsin B and L (CatB/L) and the serine protease TMPRSS2 were required for coronavirus S protein priming in target cells (Simmons et al., 2005; Glowacka et al., 2011). We next investigated the effect of S protein mutations in N501Y.V1 and N501Y.V2 on protease dependent entry in 293T-hACE2 cells (Supplementary Figures S4A, B). E64d was attenuated in 293T-hACE2-TMPRSS2 cells, indicating that CatB/L is the dominant proteases required for priming of SARS-CoV-2 S protein in TMPRSS2 cells. Compared with 293T-hACE2 cells, the inhibition efficiency of E64d was attenuated in 293T-hACE2-TMPRSS2 cells (Supplementary Figures S4A, B). Camostat, a serine protease inhibitor, cannot inhibit SARS-CoV-2 entry into 293T-hACE2 cells (Figures 5B, C), while partially reduced SARS-CoV-2 entry into 293T-hACE2-TMPRSS2 cells (Supplementary Figure S4B). Moreover, the combined inhibitory effect of E64d and Camostat in 293T-hACE2-TMPRSS2 cells was more obvious than any of
them alone (Supplementary Figure S4B). These results indicated that Cat B/L is required for priming of S protein both in TMPRSS2- and TMPRSS2+ 293T cells, while TMPRSS2 is required only in TMPRSS2+ 293T cells. More importantly, Camostat had a more significant inhibitory effect on N501Y.V1 and N501Y.V2-RBD pseudoviruses than D614G (Supplementary Figure S4B), indicating that the priming of N501Y.V1 and N501Y.V2-RBD S protein maybe more dependent on TMPRSS2 activities.

**SARS-CoV-2 Enters Cell Lines Through Endocytosis**

Previous studies have shown that SARS-CoV-2 enters target cells mainly through endocytosis (Palacios et al., 2020). Next, we evaluated whether N501Y.V1 and N501Y.V2 lineages enter into host cells through endocytosis. 293T-hACE2 and 293T-hACE2-TMPRSS2 cells were pretreated with endocytosis inhibitors Chloroquine, Tetradeine, and Apilimod, and then their effect on viruse entry was evaluated. Consistent with the previous study, all three inhibitors decreased the infection of WT, D614G N501Y.V1 and N501Y.V2-RBD pseudovirions in a dose-dependent manner (Figures 5D–F and Supplementary Figures S4C, D). Compared with 293T-hACE2 cells, the inhibition efficiency of the three inhibitors in 293T-hACE2-TMPRSS2 cells was also attenuated (Supplementary Figures S4C, D). However, compared with WT and D614G, the inhibition efficiency of these inhibitors on N501Y.V1 and N501Y.V2 RBD lineages has no significant difference (Supplementary Figures S4C, D). These results indicated that entry of N501Y.V1 and N501Y.V2-RBD pseudovirions into host cells mainly depend on the endocytosis in 293T-hACE2 cells, but presence of TMPRSS2 attenuate this dependence.

**DISCUSSION AND CONCLUSION**

As RNA virus, SARS-CoV-2 has a high mutation rate during transmission in the population. Moreover, some mutations are adaptive because they alter pathogenesis, virulence, and/or transmissibility (Zhou et al., 2020). Particularly, the D614G mutation in the spike leads to increased virus infectivity and subsequently spread rapidly in the world, thereby gradually replacing previously circulating lineages (Hou et al., 2020; Korber et al., 2020; Li et al., 2020; Plante et al., 2020). In December 2020, newly emerging SARS-CoV-2 N501Y.V1 and N501Y.V2 variants are raising concerns in the UK and South Africa respectively, due to the enhancing spread ability of the virus. It is believed that mutations of N501Y.V1 and N501Y.V2 lineages have negative effects on the infection of SARS-CoV-2. Recently, Wang et al. (2021) showed that the infectivity of pseudovirions incorporated with N501Y.V2 S proteins was not obviously higher than that of N501Y.V1. The results of our study combined with the previous study indicate that the mutation of N501Y lineages may enhance the infection efficiency of SARS-CoV-2 in several susceptible cell lines. Interestingly, the infection efficiency of N501Y.V1.RBD pseudovirus is higher than N501Y.V2, implying the non-RBD S mutations of N501Y.V2 have a negative effect on the infection of SARS-CoV-2. Recently, Li et al. (2021) showed that the infectivity of pseudovirions incorporated with N501Y.V2 S proteins was not obviously higher than that of N501Y.V1.
changed in human cells, while N501Y.V2 RBD mutations slightly but obviously increase the viral infection efficiency, which is consistent with our research. Previous studies in mice have shown that N501Y can increase the affinity for the mouse ACE2 receptor (Gu et al., 2020), which proves that this new variant can enhance its infectivity in the host. Kuzmina et al. (Kuzmina et al., 2021) reported that pseudovirions with N501Y +K417N or N501Y+E484K exhibited higher infection rates than the N501Y pseudovirus alone. Indeed, N501Y.V3 lineage includes three mutations in the RBD region (K417T, E484K and N501Y), and it almost has the same three mutations present in RBD as N501Y.V2 lineage, except for K417N/T substitution. These three RBD mutations of S protein may cause the higher infection efficiency of N501Y.V2 and N501Y.V3 via promoting the binding affinity with ACE2 (Khan et al., 2021). Therefore, the mutation sites of N501, E484 and K417 in RBD region are essential for virus infectivity. Compared with D614G, N501Y.V1 lineage had no significant change in infectivity. In 293T-hACE2 cells, the infection efficiency of N501Y.V1 was slightly lower than D614G; however, in cells expressed TMPRSS2, such as 293T-hACE2-TMPRSS2 and Caco-2 cells, its infectivity increased. These results indicate that the infection of N501Y.V1 lineage may be more dependent on TMPRSS2 activity. The effects of single-site mutations of N501Y.V1 and N501Y.V2 lineages on viral infectivity were variable. Pseudovirion with HV69-70 deletion could enhance the infectivity of the virus, while single-site mutation T716I, A570D, D118H, and A701V caused a modest reduction in viral infectivity. So, the infectivity of SARS-CoV-2 may be associated with the synergistic effects of different mutations, particularly the mutations in RBD region of S protein.

Priming of SARS-CoV S proteins by target cell proteases is crucial for virus entry into cells (Głowacka et al., 2011; Li, 2015). SARS-CoV-2 spike protein could be cleaved in cells, and the cleaved S protein was incorporated into VSV pseudovirions (Hoffmann et al., 2020b). In our study, the S protein of SARS-CoV-2 and its mutations were weakly cleaved in cells, and there was no significant difference between these mutants. Previous studies show that the cleavage efficiency of S protein into S1/S2 regulates virus infection (Hoffmann et al., 2020a). We compared the cleavage of S protein in WT, D614G, N501Y.V1 and N501Y.V2 RBD pseudovirions. To our surprise, the cleaved S protein band was slightly weakened in particles of N501Y.V1 than WT and D614G (Figure 1B). However, N501Y.V2 lineage, which is more infectious in cell lines, had no substantial differences in spike cleavage than WT and D614G virions, suggesting that the enhanced virus infectivity of N501Y.V2 lineage is not likely due to the difference of S protein cleavage.

It is reported that SARS-CoV-2 D614G mutant has a higher thermal stability than WT virions, and its strong infectivity and transmissibility may be related to the stability of the virus (Plante et al., 2020). However, it is reported that there is no significant difference among the stability of N501Y.V1, N501Y.V2 and N501Y.V3 pseudoviruses, which is incubated at 33°C for a period of time (Hoffmann et al., 2021). To better detect the thermal stability of SARS-CoV-2 variants virions in the host, we choose 37°C (normal body temperature) and 42°C (possible body temperature in fever) for treating virus. Importantly, we found that N501Y.V1 and N501Y.V2 lineages are more stable than D614G, indicating that the enhanced infectivity of N501Y.V1 and N501Y.V2 lineages in the population may be partly correlated with its higher thermal stability in the host and environment. The inconsistency between the research results is probably caused by the incubation temperature. The pseudovirion will be more unstable at 37°C and 42°C than 33°C, making the difference in thermal stability manifest. Moreover, the thermal stability of N501Y.V2 pseudovirus is higher than N501Y.V2 RBD, implying the non-RBD mutations of N501Y.V2 have positive effect on the thermal stability of SARS-CoV-2. We further evaluated the effect of single-site mutations of N501Y.V1 and N501Y.V2 lineages on the stability of the virus. We found that several single-site mutations of N501Y.V1 and N501Y.V2 lineages can increase/
decrease the thermal stability of pseudovirion. Therefore, the higher stability of N501Y.V1 and N501Y.V2 lineages may be related to the synergistic effects of different mutations.

SARS-CoV S protein is primed by the endosomal cysteine CatB/L protease in TMPRSS2- cells (Simmons et al., 2005; Zhou et al., 2016). However, S protein priming by TMPRSS2 is also critical for viral entry into host cells (Kawase et al., 2012; Zhou et al., 2015; Iwata-Yoshikawa et al., 2019). Recent studies show that SARS-CoV-2 entry target cells depends on CatB/L and/or TMPRSS2 activity (Iwata-Yoshikawa et al., 2019; Hoffmann et al., 2020b; Hoffmann et al., 2021). The present study indicates that CatB/L is required for all SARS-CoV-2 variants entry in TMPRSS2- cells, while TMPRSS2 is required for priming of all SARS-CoV-2 variants entry into TMPRSS2+ cells. More importantly, Camostat has a better inhibition effect on N501Y.V1 and N501Y.V2 lineages than D614G in TMPRSS2+ cells, indicating that the priming of N501Y.V1 and N501Y.V2 S protein maybe more dependent on TMPRSS2 activity.

In this study, we demonstrated that the infectivity of SARS-CoV-2 N501Y.V2 was increased in susceptible cells, and the enhanced virus infectivity was not likely related to the cleavage of S protein. We further found that SARS-CoV-2 N501Y.V1 and N501Y.V2 mutants are more thermal stable in the host and environment, which may be associated with the rapid transmission of the two variants in the population. Finally, we proved that SARS-CoV-2 WT, D614G, N501Y.V1 and N501Y.V2 entry into host cells mainly through endocytosis, while both cathepsin and TMPRSS2 play important roles in virus entry. However, in view of the limitations of pseudoviruses and immortalized cell lines used in this study, our findings still need to be verified using infectious live virus and primary cells or tissues in future studies. In conclusion, our study plays a vital role in understanding the evolution and infectivity of SARS-CoV-2 variants, as well as the development of COVID-19 therapeutic drugs.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

AUTHOR CONTRIBUTIONS

HT performed the experiments and wrote the manuscript. HT and XD analyzed data. LG, ZW, FM, XZ, YS, XS, SQ, and JA contributed to revise the manuscript and approved the final manuscript. XD and FQ was responsible for research design, strategy and supervision. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by: The National Natural Science Foundation of China (Grant 81701567, 81773058 and
Supplementary Figure 2 | DNA sequencing results of S gene mutations of N501Y.V1, N501Y.V2-RBD and N501Y.V2. SARS-CoV-2 S genes were sequenced with Sanger’s DNA sequencing at Genewiz Biotechnology Co., Ltd. The DNA sequences of SARS-CoV-2 S mutants were compared with SARS-CoV-2 WT S gene with SnapGene software, and the related nucleotide mutation sites were marked in red boxes.

Supplementary Figure 2 | Infection efficiency of SARS-CoV-2: N501Y.V2 in mammalian cell lines. Infection efficiency of SARS-CoV-2 WT, D614G, N501Y.V2 and N501Y.V2 RBD variants in 293T-hACE2 (A), Vero (B), 293T-hACE2-TMPRSS2 (C), Caco2 (D), Caco2-hACE2 (E) cells. ns represents no significant difference, p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) , p < 0.0001 (****).

Supplementary Figure 3 | SARS-CoV-2 N501Y.V2 is more thermal stable than WT and D614G. SARS-CoV-2 WT, D614G, N501Y.V2 and N501Y.V2 RBD S pseudovirions were incubated in cell culture medium DMEM at 37°C for 4 h (A) and 6 h (B) or 42°C for 4 h (C) and 6 h (D). The viruses were quantified for their infectious levels by luciferase on 293T-hACE2 cells. The infection efficiency of remaining viruses were normalized by the average fluorescence values at 0 h. ns represents no significant difference, p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) , p < 0.0001 (****).

Supplementary Figure 4 | The effects of protease and endocytosis pathway inhibitors on the entry of SARS-CoV-2 N501Y.V1 and N501Y.V2 RBD. (A, B) Effect of CatB or TMPRSS2 on SARS-CoV-2 N501Y.V1 and N501Y.V2-RBD entry into host cells. EB4d (0.4 μM), Camostat (50 μM) or the combination of them (EB4d (0.4 μM) + Camostat (50 μM) were added into 293T-hACE2 (A) or 293T-hACE2-TMPRSS2 (B) cells 2 h prior to transduction. The luciferase activity was measured 24 h post transduction. (C, D) Effect of endocytosis on SARS-CoV-2 N501Y.V1 and N501Y.V2 RBD entry into host cells. Endocytosis inhibitors Chloroquine (1 μM), Tetradsine (0.2 μM), and Apilimod (5 nM) were added into 293T-hACE2 (C) or 293T-hACE2-TMPRSS2 (D) cells 2 h prior to transduction. Experiments were done in 4 replicates and repeated at least twice. One representative is shown with error bars indicating SEM. ns represents no significant difference, p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) , p < 0.0001 (****).

REFERENCES
Baum, A., Fulton, B. O., Wloga, E., Copin, R., Pascal, K. E., Russo, V., et al. (2020). Antibody Cocktail to SARS-CoV-2 Spike Protein Prevents Rapid Mutational Escape Seen With Individual Antibodies. Science 369, 1014–1018. doi: 10.1126/science.abc0831
Belouard, S., Chu, V. C., and Whittaker, G. R. (2009). Activation of the SARS Coronavirus Spike Protein via Sequential Proteolytic Cleavage at Two Distinct Sites. Proc. Natl. Acad. Sci. U. S. A. 106, 5871–5876. doi: 10.1073/pnas.0809524106
Benton, D. J., Wrobel, A. G., Xu, P., Roustan, C., Martin, S. R., Rosenthal, P. B., Baum, A., Fulton, B. O., Wloga, E., Copin, R., Pascal, K. E., Russo, V., et al. (2020). Effect of CatB or TMPRSS2 on SARS-CoV-2 N501Y.V1 and N501Y.V2-RBD entry into host cells. EB4d (0.4 μM), Camostat (50 μM) or the combination of them (EB4d (0.4 μM) + Camostat (50 μM) were added into 293T-hACE2 (A) or 293T-hACE2-TMPRSS2 (B) cells 2 h prior to transduction. The luciferase activity was measured 24 h post transduction. (C, D) Effect of endocytosis on SARS-CoV-2 N501Y.V1 and N501Y.V2 RBD entry into host cells. Endocytosis inhibitors Chloroquine (1 μM), Tetradsine (0.2 μM), and Apilimod (5 nM) were added into 293T-hACE2 (C) or 293T-hACE2-TMPRSS2 (D) cells 2 h prior to transduction. Experiments were done in 4 replicates and repeated at least twice. One representative is shown with error bars indicating SEM. ns represents no significant difference, p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) , p < 0.0001 (****).

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., HERRLER, T., ERICHSEN, S., et al. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181, 271–280.e278. doi: 10.1016/j.cell.2020.02.052
Hou, Y. J., Chiba, S., Halfmann, P., Ehre, C., Kuroda, M., Dinnon, K. H., et al. (2020). SARS-CoV-2 D614G Variant Exhibits Efficient Replication Ex Vivo and Transmission. Virus Sci. 370, 1464–1468. doi: 10.1002/evir.6499
Hulsit, R. J., De Haan, C. A., and Bosch, B. J. (2016). Coronavirus Spike Protein and Tropism Changes. Adv. Virus Res. 96, 29–57. doi: 10.1016/bs.avir.2016.08.004
Iwata-Yoshikawa, N., Okamura, T., Shimizu, Y., Hasegawa, H., Takeda, M., and Nagata, N. (2019). TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models After Coronavirus Infection. J. Virol. 93 (6), e01815–18. doi: 10.1128/JVI.01815-18
James, S. E., Ngcapu, S., Kanzi, A. M., Tegally, H., Fonseca, V., Giandhari, J., et al. (2020). High Resolution Analysis of Transmission Dynamics of Sars-Cov-2 in Two Major Hospital Outbreaks in South Africa Leveraging Intrahost Diversity. medRxiv 2020.11.15.20231993. doi: 10.1101/2020.11.15.20231993
Kawase, M., Shirato, K., van der Hoek, L., Taguchi, F., and Matsuyama, S. (2012). Simultaneous Treatment of Human Bronchiolar Epithelial Cells With Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus Entry. J. Virol. 86, 6537–6545. doi: 10.1128/JVI.00094-12
Khan, A., Zia, T., Suleman, M., Khan, T., Ali, S. S., Abbasi, A. A., et al. (2021). Higher Infectivity of the SARS-CoV-2 New Variants Is Associated With K417N/T, E484K, and N501Y Mutants: An Insight From Structural Data. J. Cell Physiol. 236 (10), 7045–7057. doi: 10.1002/jcp.30637
Kirby, T. (2021). New Variant of SARS-CoV-2 in UK Causes Surge of COVID-19. Lancet Respir. Med. 9, e20–e21. doi: 10.1016/S2213-2600(21)00005-9
Kuzmina, A., Khalaila, Y., Voloshin, O., Keren-Naus, A., Boehm-Cohen, L., Raviv, Y., et al. (2021). SARS-CoV-2 Spike Variants Exhibit Differential Infectivity and Neutralization Resistance to Convalescent or Post-Vaccination Sera. Cell Host Micrbo 29, 522–528.e522. doi: 10.1016/j.chom.2021.03.008
Li, F. (2015). Receptor Recognition Mechanisms of Coronaviruses: A Decade of Immunopathology in the Airways of Murine Models After Coronavirus Infection. J. Virol. 90, 154–166. doi: 10.1128/JVI.02615-14
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., et al. (2003). Angiotensin-Converting Enzyme 2 Is a Functional Receptor for the SARS Coronavirus. Nature 426, 440–444. doi: 10.1038/nature02398

Li, Q., Nie, J., Wu, J., Zhang, L., Ding, R., Wang, H., et al. (2021). SARS-CoV-2 501Y-V2 Vectors Lack Infectivity But do Have Immune Escape. Cell 184, 2362–2371.e2369. doi: 10.1016/j.cell.2021.02.042

Li, Q., Wu, J., Nie, J., Zhang, L., Hao, H., Liu, S., et al. (2020). The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. Cell 182, 1284–1294.e1289. doi: 10.1016/j.cell.2020.07.012

Lv, M., Luo, X., Estill, J., Liu, Y., Ren, M., Wang, J., et al. (2020). Coronavirus Disease (COVID-19): A Scoping Review. Euro Surveill 25 (15), 2000125. doi: 10.2807/1560-7917.ES.2020.25.15.2000125

Makoni, M. (2021). South Africa Responds to New SARS-CoV-2 Variant. Lancet 397, 267. doi: 10.1016/S0140-6736(21)00144-6

Millet, J. K., and Whittaker, G. R. (2014). Host Cell Entry of Middle East Lv, M., Luo, X., Estill, J., Liu, Y., Ren, M., Wang, J., et al. (2020). Coronavirus Nature 579, 270. doi: 10.1038/s41586-020-2895-3

Li, Q., Wu, J., Hao, H., Liu, S., et al. (2020a). Establishment and Validation of a Pseudovirus Neutralization Assay for SARS-CoV-2. Emerg. Microbes Infect. 9, 680–686. doi: 10.1002/22221751.2020.1743767

Palacios, R., Patiño, E. G., De Oliveira Piorelli, R., Conde, M., Batista, A. P., Zeng, G., et al. (2020). Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Treating Healthcare Professionals With the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A Structured Summary of a Study Protocol for a Randomised Controlled Trial. Trials 21, 853. doi: 10.1186/s13063-020-04775-4

Plante, J. A., Liu, Y., Liu, J., Xia, H., Johnson, B. A., Lokugamage, K. G., et al. (2020). Spike Mutation D614G Alters SARS-CoV-2 Fitness. Nature 592 (7852), 116–121. doi: 10.1038/s41586-020-2895-3

Roquebert, B., Trombert-Paolontani, S., Haim-Boukhobza, S., Lecorche, E., Verduline, L., Foulongne, V., et al. (2021). The SARS-CoV-2 B.1.351 Lineage (VOC B) Is Outgrowing the B.1.1.7 Lineage (VOC E) in Some French Regions in April 2021. Euro Surveil 26 (23), 2100447. doi: 10.2807/1560-7917.ES.2021.26.23.2100447

Rubin, E. J., Baden, L. R., Abdool Karim, S. S., and Morrissey, S. (2021). Audio Interview: Covid-19 in South Africa and a New SARS-CoV-2 Variant. N Engl. J. Med. 384, e14. doi: 10.1056/NEJMe2100736

Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., et al. (2020). Structural Basis of Receptor Recognition by SARS-CoV-2. Nature 581, 221–224. doi: 10.1038/s41586-020-2179-y

Simmons, G., Gosalba, D. N., Rennekamp, A. J., Reeves, J. D., Diamond, S. L., and Bates, P. (2005). Inhibitors of Cathepsin L Prevent Severe Acute Respiratory Syndrome Coronavirus Entry. Proc. Natl. Acad. Sci. U. S. A. 102, 11876–11881. doi: 10.1073/pnas.0505577102

Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., et al. (2021). Detection of a SARS-CoV-2 Variant of Concern in South Africa. Nature 592, 438–443. doi: 10.1038/s41586-021-03402-9

Walls, A. C., Park, Y. J., Tortorici, M. A., Wall, A., McGwire, A. T., and Veesler, D. (2020). Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 181, 281–292.e286. doi: 10.1016/j.cell.2020.02.058

Wang, P., Nair, M. S., Liu, L., Ikteni, S., Luo, Y., Guo, Y., et al. (2021). Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. Nature 593, 130–135. doi: 10.1038/s41586-021-03398-2

Wan, Y., Shang, J., Graham, R., Baric, R. S., and Li, F. (2020). Receptor Recognition by the Novel Coronavirus From Wuhan: An Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J. Virol. 94 (7), e00127–20. doi: 10.1128/JVI.00127-20

Watanabe, Y., Allen, J. D., Wrapp, D., Mcclellan, J. S., and Crispin, M. (2020). Site-Specific Glycan Analysis of the SARS-CoV-2 Spike. Science 369, 330–333. doi: 10.1126/science.abb9983

Weisblum, Y., Schmidt, E., Zhang, F., Dasilva, J., Poston, D., Lorenzi, J. C., et al. (2020). Escape From Neutralizing Antibodies by SARS-CoV-2 Spike Protein Variants. Elife 9, e61312. doi: 10.7554/eLife.61312

Whitt, M. A. (2010). Generation of VSV Pseudotypes Using Reombinant ΔpVSV for Studies on Virus Entry, Identification of Entry Inhibitors, and Immune Responses to Vaccines. J. Virol. Methods 169, 365–374. doi: 10.1016/j.jviromet.2010.08.006

Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhanda, M., Kaguudi, P., Lambson, B. E., et al. (2021). SARS-CoV-2 501y.V2 Escapes Neutralization by South African COVID-19 Donor Plasma. Nat. Med. 27 (4), 622–625. doi: 10.1038/s41591-021-01285-x

Zettl, F., Meister, T. L., Vollmer, T., Fischer, B., Steinmann, J., Krawczyk, A., et al. (2020). Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using Propagation-Defective Vesicular Stomatitis Virus Pseudotypes. Vaccines (Basel) 8 (3), 386. doi: 10.3390/vaccines8030386

Zhou, N., Pan, T., Zhang, J., Li, Q., Zhang, X., Bai, C., et al. (2016). Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV). J. Biol. Chem. 291, 9218–9232. doi: 10.1074/jbc.M116.716100

Zhou, Y., Vedantham, P., Lu, K., Aguado, J., Carrion, R. J., Nunnely, J. W., et al. (2015). Protease Inhibitors Targeting Coronavirus and Filovirus Entry. Antiviral Res. 116, 74–84. doi: 10.1016/j.antiviral.2015.01.011

Zhou, P., Yang, X. L., Wang, X. G., Hu, B., Zhang, L., Zhang, W., et al. (2020). A Pneumonia Outbreak Associated With a New Coronavirus of Probable Bat Origin. Nature 579, 270–273. doi: 10.1038/s41586-020-2122-7

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Tang, Gao, Wu, Meng, Zhao, Shao, Shi, Qiao, An, Du and Qin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.